المؤلفون: L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev, Л. В. Федина, И. Н. Сычев, Т. Д. Растворова, Е. В. Стригункова, А. А. Качанова, Ж. А. Созаева, П. О. Бочков, А. В. Варданян, К. Б. Мирзаев, Д. А. Сычев

المساهمون: This work was supported by Russian Science Foundation grant 22-15-00251 №122060600001-4, Работа выполнена при поддержке гранта Российского научного фонда 22-15-00251 №122060600001-4

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 6 (2022); 624-629 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 6 (2022); 624-629 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: ривароксабан, pharmacogenetics, ABCB1, drug interactions, apixaban, rivaroxaban, фармакогенетика, межлекарственные взаимодействия, апиксабан

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2848/2375; Kruger PC, Eikelboom JW, Douketis JD, et al. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019;210(11):516-24. DOI:10.5694/mja2.50201.; Brighton T. New oral anticoagulant drugs - mechanisms of action. Aust Prescr. 2010;33:38-41. DOI:10.18773/austprescr.2010.017.; Benamouzig R, Guenoun M, Deutsch D, et al. Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. Cardiovasc Drugs Ther. 2022;36(5):973-89. DOI:10.1007/s10557-021-07211-0; Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272-74. DOI:10.1056/NEJMp1302834.; Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-44. DOI:10.1161/STROKEAHA.118.020232.; Overvad TF, Larsen TB, Albertsen IE, et al. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2013;11(12):1619-29. DOI:10.1586/14779072.2013.839214.; Скрипка А.И., Когай В.В., Листратов А.И. и др. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике. Тер Архив. 2019;91(7):111-20. DOI:10.26442/00403660.2019.07.000045.; Byon W, Garonzik S, Boyd RA, et al. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265-79. DOI:10.1007/s40262-019-00775-z.; Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341-50. DOI:10.1016/j.jacc.2019.12.068.; PharmGKB [cited 2022 Oct 13]. Available from: https://www.pharmgkb.org/.; Online Calculator of Hardy-Weinberg equilibrium. WpCalc. [cited 2022 Oct 2]. Available from: https://wpcalc.com/en/equilibrium-hardy-weinberg/.; Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021;11(1):37. DOI:10.3390/jpm11010037.; Xie Q, Xiang Q, Mu G, et al. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. Curr Pharm Des. 2018;24(30):3558-65. DOI:10.2174/1381612824666181018153641.; Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-83. DOI:10.1111/jth.13577.; Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. High Blood Press Cardiovasc Prev. 2019;26(5):413-20. DOI:10.1007/s40292-019-00342-4.; Sychev D, Ostroumova O, Cherniaeva M, et al. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation. High Blood Press Cardiovasc Prev. 2022;29(5):469-80. DOI:10.1007/s40292-022-00536-3.; Dimatteo C, D’Andrea G, Vecchione G, et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016;145:24-6. DOI:10.1016/j.thromres.2016.07.005.; Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018;11:43-9. DOI:10.2147/PGPM.S157111.; Terrier J, Gaspar F, Fontana P, et al. Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. Am J Med. 2021;134(8):939-42. DOI:10.1016/j.amjmed.2021.04.003.; Vakkalagadda B, Frost C, Byon W, et al. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119-27. DOI:10.1007/s40256-015-0157-9.; Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838-46. DOI:10.1111/bcp.12541.; Mikus G, Foerster KI, Schaumaeker M, et al. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol. 2020;86(8):1632-41. DOI:10.1111/bcp.14277.; Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. DOI:10.1111/bcp.12075.; Bartlett JW, Renner E, Mouland E, et al. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother. 2019;53(1):21-7. DOI:10.1177/1060028018795140.; Pham P, Schmidt S, Lesko L, et al. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. JAMA Netw Open. 2020;3(4):e203593. DOI:10.1001/jamanetworkopen.2020.3593.; Mar PL, Gopinathannair R, Gengler BE, et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022;15(6):e007956. DOI:10.1161/CIRCEP.121.007956.; https://www.rpcardio.com/jour/article/view/2848

الاتاحة: https://www.rpcardio.com/jour/article/view/2848
https://doi.org/10.20996/1819-6446-2022-12-02

المؤلفون: V. A. Evteev, N. D. Bunyatyan, E. Yu. Demchenkova, A. B. Prokofiev, В. А. Евтеев, Н. Д. Бунятян, Е. Ю. Демченкова, А. Б. Прокофьев

المساهمون: The study reported in this publication was carried out as part of publicly funded research project No. 056- 00052-23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D registration No. 121022400082-4)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056- 00052-23-00 на проведение прикладных научных исследований (номер государственного учета НИР 121022400082-4)

المصدر: Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation; Том 13, № 4 (2023); 560-566 ; Ведомости Научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств; Том 13, № 4 (2023); 560-566 ; 2619-1172 ; 1991-2919

مصطلحات موضوعية: регуляторные требования, drug–drug interactions, transporters, pharmacokinetic models, regulatory requirements, межлекарственные взаимодействия, транспортеры лекарственных средств, фармакокинетические модели

وصف الملف: application/pdf

Relation: https://www.vedomostincesmp.ru/jour/article/view/557/1219; https://www.vedomostincesmp.ru/jour/article/view/557/1227; https://www.vedomostincesmp.ru/jour/article/view/557/1236; https://www.vedomostincesmp.ru/jour/article/view/557/1246; Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48(6):662–70. https://doi.org/10.1177/0091270007312153; DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–7. https://doi.org/10.1038/clpt.2009.295; Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14. https://doi.org/10.1038/nrd3078; Zamek-Gliszczynski MJ, Sangha V, Shen H, Feng B, Wittmer MB, Varma MVS, et al. Transporters in drug development: International transporter consortium update on emerging transporters of clinical importance. Clin Pharmacol Ther. 2022;112(3):485–500. https://doi.org/10.1002/cpt.2644; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028; Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, et al. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm. 2012;9(9):2497–504. https://doi.org/10.1021/mp300108c; Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, et al. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res. 2009;15(9):3084–93. https://doi.org/10.1158/1078-0432.ccr-08-2940; Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17(8):2127–35. https://doi.org/10.1681/asn.2006030205; Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug–drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012;340(2):393–403. https://doi.org/10.1124/jpet.111.184986; Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185–91. https://doi.org/10.1124/jpet.108.147918; Frymoyer A, Shugarts S, Browne M, Wu AHB, Frassetto L, Benet LZ. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010;88(4):540–7. https://doi.org/10.1038/clpt.2010.142; Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res. 2007;24(9):1720–8. https://doi.org/10.1007/s11095-007-9278-4; Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JHM. The effect of Pgp (Mdr1a/1b), BCRP (Bcrp1) and Pgp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs. 2009;27(1):31–40. https://doi.org/10.1007/s10637-008-9138-z; Chen C, Stock JL, Liu X, Shi J, Van Deusen JW, Di- Mattia DA, et al. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos. 2008;36(9):1840–5. https://doi.org/10.1124/dmd.108.020594; Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther. 2006;317(2):579–89. https://doi.org/10.1124/jpet.105.098665; https://www.vedomostincesmp.ru/jour/article/view/557

الاتاحة: https://www.vedomostincesmp.ru/jour/article/view/557
https://doi.org/10.30895/1991-2919-2023-13-4-560-566

المؤلفون: O. O. Kirilochev, A. R. Umerova

المصدر: Качественная клиническая практика, Vol 0, Iss 3, Pp 85-92 (2020)

مصطلحات موضوعية: межлекарственные взаимодействия, неблагоприятные лекарственные реакции, психические заболевания, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/512; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

URL الوصول: https://doaj.org/article/39fd242c39474fc385e83e548b9bea8c

المؤلفون: O. V. Gaisenok, Yu. M. Chichkov, M. V. Leonova, О. В. Гайсёнок, Ю. М. Чичков, М. В. Леонова

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 5 (2022); 585-590 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 5 (2022); 585-590 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: рабдомиолиз, ticagrelor, drug-drug interactions, side effects, rhabdomyolysis, тикагрелор, межлекарственные взаимодействия, побочные эффекты

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2827/2365; World Health Organization: Cardiovascular diseases (CVDs). Key facts [cited 2021 Aug 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).; Roy D, Mahapatra T, Manna K, et al. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. PLoS One. 2020;15(5):e0233230. DOI:10.1371/journal.pone.0233230.; Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008-2024. DOI:10.1001/jama.2015.15629.; Newman CB, Preiss D, Tobert JA, et al.; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. DOI:10.1161/ATV.0000000000000073.; Ould-Nana I, Cillis M, Gizzi M, et al. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature. J Oncol Pharm Pract. 2021;27(1):216-9. DOI:10.1177/1078155220923001.; Miller PE, Martin SS. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep. 2016;18(5):20. DOI:10.1007/s11883-016-0578-1.; Collet JP, Thiele H, Barbato E, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. DOI:10.1093/eurheartj/ehaa575; Kido K, Wheeler MB, Seratnahaei A, et al. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc (2003). 2015;55(3):320-3. DOI:10.1331/JAPhA.2015.14151.; Banakh I, Haji K, Kung R, et al. Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor. Case Rep Crit Care. 2017;2017:3801819. DOI:10.1155/2017/3801819.; Samuel G, Atanda AC, Onyemeh A, et al. A Unique Case of Drug Interaction between Ticagrelor and Statin Leading to Acute Renal Failure. Cureus. 2017;9(8):e1633. DOI:10.7759/cureus.1633.; Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. Am J Case Rep. 2017;18:1238-41. DOI:10.12659/ajcr.905974.; New J, Le K, Wong K, et al. A case of acute renal failure and rhabdomyolysis associated with the concomitant use of Ticagrelor, Rosuvastatin and Losartan. JMS Intern Med 2017;2:1004 [cited 2021 Aug 14]. Available from: https://www.jscimedcentral.com/InternalMedicine/internalmedicine-2-1004.pdf.; Park IS, Lee SB, Song SH, et al. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis. Anatol J Cardiol. 2018;19(3):225-6. DOI:10.14744/AnatolJCardiol.2017.8200.; Sarinic VM, Sandberg L, Hartman J, Caduff-Janosa P. Interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysis. WHO Pharm Newsl. 2018;3:10-4 [cited 2021 Aug 10]. Available from: https://www.who-umc.org/media/164007/rhabdomyolysisweb.pdf.; Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs. 2018;78(11):1105-12. DOI:10.1007/s40265-018-0947-x.; Martín Navarro JA, Gutiérrez Sánchez MJ, Petkov Stoyanov V, Jiménez Herrero MC. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin. Nefrologia (Engl Ed). 2019;39(4):448-50. DOI:10.1016/j.nefro.2018.10.012.; Sibley RA, Katz A, Papadopoulos J. The Interaction Between Rosuvastatin and Ticagrelor Leading to Rhabdomyolysis: A Case Report and Narrative Review. Hosp Pharm. 2021;56(5):537-42. DOI:10.1177/0018578720928262.; Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455.; Furtado RHM, Giugliano RP. What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Cardiol Ther. 2020;9(1):59-73. DOI:10.1007/s40119-020-00163-w.; Kariyanna PT, Haseeb S, Chowdhury YS, et al. Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review. Am J Med Case Rep. 2019;7(12):337-41. DOI:10.12691/ajmcr-7-12-9.; Vrkić Kirhmajer M, Macolia Šarinić V, Šimičević L, et al. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile. Basic Clin Pharmacol Toxicol. 2018;123(4):509-18. DOI:10.1111/bcpt.13035.; DiNicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol. 2012;35(11):647-8. DOI:10.1002/clc.22063.; Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503-9. DOI:10.1016/j.jacc.2014.03.031.; Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 2003;12(5):497-502. DOI:10.1097/00041552-200309000-00003.; Wallentin L, Becker RC, Budaj A, et al, PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. DOI:10.1056/ NEJMoa0904327.; Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165(5):1260-87. DOI:10.1111/j.1476-5381.2011.01724.x.; Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34(10):1077-90. DOI:10.1002/phar.1477.; Goard CA, Mather RG, Vinepal B, et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer. 2010;127(12):2936-48. DOI:10.1002/ijc.25295.; El Kantar S, Nehmeh B, Saad P, et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today. 2020;25(10):1822-38. DOI:10.1016/j.drudis.2020.08.002.; Mallhi TH, Khan YH, Adnan AS. Stratification of Acute Kidney Injury in COVID-19. Am J Trop Med Hyg. 2020;103(6):2164-7. DOI:10.4269/ajtmh.20-0794.; Aygün İ, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep. 2020;10(1):21508. DOI:10.1038/s41598-020-78697-1.; Varenhorst C, Eriksson N, Johansson Å, et al, PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901-12. DOI:10.1093/eurheartj/ehv116.; Liu JE, Liu XY, Chen S, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017;73(11):1409-16. DOI:10.1007/s00228-017-2318-z.; Gaisenok O. Pandemic of Fear or what Statistics Hide: Patients with Cardiovascular Disease are at Increased Risk During COVID-19. International Cardiovascular Forum Journal. 2020;21:2-6. DOI:10.17987/icfj.v21i0.711.; Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30. DOI:10.7326/0003-4819-158-11-201306040-00007.; https://www.rpcardio.com/jour/article/view/2827

الاتاحة: https://www.rpcardio.com/jour/article/view/2827
https://doi.org/10.20996/1819-6446-2022-10-03

المؤلفون: I. N. Sychev, L. V. Fedina, D. A. Gabrielyan, T. D. Rastvorova, E. V. Strigunkova, K. B. Mirzayev, D. A. Sychev, И. Н. Сычев, Л. В. Федина, Д. А. Габриелян, Т. Д. Растворова, Е. В. Стригункова, К. Б. Мирзаев, Д. А. Сычев

المساهمون: Работа была поддержана грантом РНФ №22-15-00251 «Персонализированное применение прямых оральных антикоагулянтов на основе фармакогеномного подхода».

المصدر: Meditsinskiy sovet = Medical Council; № 17 (2022); 52-64 ; Медицинский Совет; № 17 (2022); 52-64 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: кровотечения, interdrug interactions, CYP3A4, P-glycoprotein, bleeding, межлекарственные взаимодействия, P-гликопротеин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7111/6384; Payne R.A. The Epidemiology of Polypharmacy. Clin Med (Lond). 2016;16(5):465–469. https://doi.org/10.7861/clinmedicine.16-5-465.; Foerster K.I., Hermann S., Mikus G., Haefeli W.E. Drug-Drug Interactions with Direct Oral Anticoagulants. Clin Pharmacokinet. 2020;59(8):967–980. https://doi.org/10.1007/s40262-020-00879-x.; Leelakanok N., Holcombe A.L., Lund B.C., Gu X., Schweizer M.L. Association between Polypharmacy and Death: A Systematic Review and Meta-Analysis. J Am Pharm Assoc (2003). 2017;57(6):729–738.e10. https://doi.org/10.1016/j.japh.2017.06.002.; Franco Moreno A.I., Martín Díaz R.M., García Navarro M.J. Direct Oral Anticoagulants: An Update. Med Clin (Barc). 2018;151(5):198–206. https://doi.org/10.1016/j.medcli.2017.11.042.; Бойцов С.А., Лукьянов М.М., Платонова Е.В., Горбунов В.М., Романчук С.В., Назарова O.A. и др. Оценка эффективности вакцинопрофилактики гриппа по данным проспективного контроля у лиц, находящихся под диспансерным наблюдением по поводу болезней системы кровообращения. Рациональная фармакотерапия в кардиологии. 2016;(6):703–710. https://doi.org/10.20996/1819-6446-2016-12-6-703-710.; Murphy J.E. Clinical Pharmacokinetics. 2017. 429 р.; Eriksson B.I., Quinlan D.J., Weitz J.I. Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. Clin Pharmacokinet. 2009;48(1):1–22. https://doi.org/10.2165/0003088-200948010-00001.; Gong I.Y., Kim R.B. Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban. Can J Cardiol. 2013;29(7 Suppl.):S24–33. https://doi.org/10.1016/j.cjca.2013.04.002.; Gerk P.M., Sara E. Rosenbaum. Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook and Computer Simulations. Hoboken NJ: John Wiley & Sons, Inc.; 2011. 430 р.; Holm J., Mannheimer B., Malmström R.E., Eliasson E., Lindh J.D. Bleeding and Thromboembolism Due to Drug-Drug Interactions with Non-Vitamin K Antagonist Oral Anticoagulants-a Swedish, Register-Based Cohort Study in Atrial Fibrillation Outpatients. Eur J Clin Pharmacol. 2021;77(3):409–419. https://doi.org/10.1007/s00228-020-03015-7.; Hakeam H.A., Al-Sanea N. Effect of Major Gastrointestinal Tract Surgery on the Absorption and Efficacy of Direct Acting Oral Anticoagulants (DOACs). J Thromb Thrombolysis. 2017;43(3):343–351. https://doi.org/10.1007/s11239-016-1465-x.; Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. The 2018 European Heart Rhythm Association Practical Guide on the Use of NonVitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Eur Heart J. 2018;39(16):1330–1393. https://doi.org/10.1093/eurheartj/ehy136.; Булаев В.М., Ших Е.В., Сычев Д.А. Безопасность и эффективность лекарственных растений. М.; 2013. 270 с. Bulaev V.M., Shikh E.V., Sychev D.A. Safety and efficacy of medicinal plants. Moscow; 2013. 270 р. (In Russ.); Pai M.P., Momary K.M., Rodvold K.A. Antibiotic Drug Interactions. Med Clin North Am. 2006;90(6):1223–1255. https://doi.org/10.1016/j.mcna.2006.06.008.; Hu J., Xiao Y.-H., Zheng Y., Lai Y.-X., Fang X.-L., Fang Q. Clinical Characteristics and Risk Factors of Tigecycline-Associated Hypofibrinogenaemia in Critically Ill Patients. Eur J Clin Pharmacol. 2020;76(7):913–922. https://doi.org/0.1007/s00228-020-02860-w.; Shorr A.F., Lodise T.P., Corey G.R., De Anda C., Fang E., Das A.F., Prokocimer P. Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2015;59(2):864–871. https://doi.org/10.1128/AAC.03688-14.; Abdul-Aziz M.H., Alffenaar J.-W.C., Bassetti M., Bracht H., Dimopoulos G., Marriott D. et al. Antimicrobial Therapeutic Drug Monitoring in Critically Ill Adult Patients: A Position Paper. Intensive Care Med. 2020;46(6):1127– 1153. https://doi.org/10.1007/s00134-020-06050-1.; Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K.L., Furberg C.D. et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894–1909. https://doi.org/10.1161/CIRCULATIONAHA.108.191087.; Zhang Y., Souverein P.C., Gardarsdottir H., van den Ham H.A., Maitland-van der Zee A.-H., de Boer A. Risk of Major Bleeding among Users of Direct Oral Anticoagulants Combined with Interacting Drugs: A Population-Based Nested Case-Control Study. Br J Clin Pharmacol. 2020;86(6):1150–1164. https://doi.org/10.1111/bcp.14227.; Sepehri Shamloo A., Dagres N., Hindricks G. 2020 ESC guidelines on atrial fibrillation: Summary of the most relevant recommendations and innovations. Herz. 2021;46(1):28–37. https://doi.org/0.1007/s00059-020-05005-y.; Smith K. Mental Health: A World of Depression. Nature. 2014;515(7526):181. https://doi.org/10.1038/515180a.; Nicolussi S., Drewe J., Butterweck V., Meyer Zu Schwabedissen H.E. Clinical relevance of St. John’s wort drug interactions revisited. Br J Pharmacol. 2020;177(6):1212–1226. https://doi.org/10.1111/bph.14936.; Cortegiani A., Ippolito M., Greco M., Granone V., Protti A., Gregoretti C. et al. Rationale and Evidence on the Use of Tocilizumab in COVID-19: A Systematic Review. Pulmonology. 2021;27(1):52–66. https://doi.org/10.1016/j.pulmoe.2020.07.003.; Testa S., Prandoni P., Paoletti O., Morandini R., Tala M., Dellanoce C. et al. Direct Oral Anticoagulant Plasma Levels’ Striking Increase in Severe COVID-19 Respiratory Syndrome Patients Treated with Antiviral Agents: The Cremona Experience. J Thromb Haemost. 2020;18(6):1320–1323. https://doi.org/10.1111/jth.14871.; Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E. et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950–2973. https://doi.org/10.1016/j.jacc.2020.04.031.; Mar P.L., Gopinathannair R., Gengler B.E., Chung M.K., Perez A., Dukes J. et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022;15(6):e007956. https://doi.org/10.1161/CIRCEP.121.007956.; https://www.med-sovet.pro/jour/article/view/7111

الاتاحة: https://www.med-sovet.pro/jour/article/view/7111
https://doi.org/10.21518/2079-701X-2022-16-17-52-64

المؤلفون: O. V. Zhukova, I. N. Kagramanyan, A. L. Khokhlov, О. В. Жукова, И. Н. Каграманян, А. Л. Хохлов

المساهمون: This work did not have funding from outside organizations., Данная работа не имела финансирования от сторонних организаций

المصدر: Pharmacy & Pharmacology; Том 8, № 5 (2020); 316-324 ; Фармация и фармакология; Том 8, № 5 (2020); 316-324 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2020-8-5

مصطلحات موضوعية: межлекарственные взаимодействия, systemic glucocorticosteroid, IL-6 inhibitor, IL-1 inhibitor, JAK-inhibitor, “cytokine storm”, attributive statistics, drug interactions, системный глюкокортикостерод, ингибитор ИЛ-6, ингибитор ИЛ-1, ингибитора JAK, «цитокиновый шторм», атрибутивная статистика

وصف الملف: application/pdf

Relation: https://www.pharmpharm.ru/jour/article/view/739/632; https://www.pharmpharm.ru/jour/article/view/739/647; Huang X., Wei F., Hu L., Wen L., Chen K. Epidemiology and Clinical Characteristics of COVID-19 // Arch Iran Med. – 2020. – Vol. 23. – No.4. – P. 268–271. DOI:10.34172/aim.2020.09.; Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19 // Int J Antimicrob Agents. – 2020. – Vol. 55. – No.5. – P. 105955. DOI:10.1016/j.ijantimicag.2020.1059555.; Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention // JAMA. 2020. – Vol. 323. – No.13. – P. 1239–1242. DOI:10.1001/jama.2020.2648.; Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., Yu T., Wang Y., Pan S., Zou X., Yuan S., Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir Med. – 2020. – Vol. 8. – No.5. – P. 475–481. DOI:10.1016/S2213-2600(20)30079-5.; Ye Q, Wang B., Mao J. The pathogenesis and treatment of the Cytokine Storm’ in COVID-19 // J Infect. – 2020. – Vol. 80. – No.6. – P. 607–613. DOI:10.1016/j.jinf.2020.03.037; RECOVERY Collaborative Group, Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L.C., Faust S.N., Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J.K., Haynes R., Landray M.J. Dexamethasone in Hospitalized Patients with Covid-19 // N Engl J Med. – 2021. – Vol. 384, No.8. – P. 693–704. DOI:10.1056/NEJMoa2021436.; Somers E.C., Eschenauer G.A., Troost J.P., Golob J.L., Gandhi T.N., Wang L., Zhou N., Petty L.A., Baang J.H., Dillman N.O., Frame D., Gregg K.S., Kaul D.R., Nagel J., Patel T.S., Zhou S., Lauring A.S., Hanauer D.A., Martin E., Sharma P., Fung C.M., Pogue J.M. Tocilizumab for treatment of mechanically ventilated patients with COVID-19 // Clin Infect Dis. – 2020:ciaa954. DOI:10.1093/cid/ciaa954.; Shakoory B., Carcillo J.A., Chatham W.W., Amdur R.L., Zhao H., Dinarello C.A., Cron R.Q., Opal S.M. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial // Crit Care Med. – 2016. – Vol. 44. – No.2. – P. 275–81. DOI:10.1097/CCM.0000000000001402.; Cao Y., Wei J., Zou L., Jiang T., Wang G., Chen L., Huang L., Meng F., Huang L., Wang N., Zhou X., Luo H., Mao Z., Chen X., Xie J., Liu J., Cheng H., Zhao J., Huang G., Wang W., Zhou J. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. – 2020. – Vol. 146. – No.1. – P. 137–146.e3. DOI:10.1016/j.jaci.2020.05.019.; Annane D., Bellissant E., Bollaert P.E., Briegel J., Keh D., Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. – 2015. – No.12. – P. CD002243. DOI:10.1002/14651858.CD002243.pub3; WHO Living Guidance: Corticosteroids for COVID-19; URL:2020https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1; Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality // Int J Antimicrob Agents. – 2020. – Vol. 55. – No.5. – P. 105954. DOI:10.1016/j.ijantimicag.2020.105954.; Sarzi-Puttini P., Giorgi V., Sirotti S., Marotto D., Ardizzone S., Rizzardini G., Antinori S., Galli M. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? // Clin Exp Rheumatol. – 2020. – Vol. 38. – No.2. – P. 337–342.; Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J.; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. – 2020. – Vol. 395. – No.10229. – P. 1033–1034. DOI:10.1016/S0140-6736(20)30628-0.; Jiang Y., Li J., Teng Y., Sun H., Tian G., He L., Li P., Chen Y., Guo Y., Li J., Zhao G., Zhou Y., Sun S. Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV // Viruses. – 2019. – Vol. 11. – No.1. – P. 39. DOI:10.3390/v11010039.; Yuan J., Zou R., Zeng L., Kou S., Lan J., Li X., Liang Y., Ding X., Tan G., Tang S., Liu L., Liu Y., Pan Y., Wang Z. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients // Inflamm Res. – 2020. – Vol. 69. – No.6. – P. 599–606. DOI:10.1007/s00011-020-01342-0.; Lu C.C., Chen M.Y., Lee W.S., Chang Y.L. Potential therapeutic agents against COVID-19: What we know so far // J Chin Med Assoc. – 2020. – Vol. 83. – No.6. – P. 534–536. DOI:10.1097/JCMA.0000000000000318; Cellina M., Orsi M., Bombaci F., Sala M., Marino P., Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab // DiagnInterv Imaging. – 2020. – Vol. 101. – No.5. – P. 323–324. DOI:10.1016/j.diii.2020.03.01; https://www.pharmpharm.ru/jour/article/view/739

الاتاحة: https://www.pharmpharm.ru/jour/article/view/739
https://doi.org/10.19163/2307-9266-2020-8-5-316-324

المؤلفون: N. Sizova V., E. Obizhaeva S., S. Mayorova O., Н. Сизова В., Е. Обижаева С., С. Майорова О.

المصدر: Journal Infectology; Том 13, № 3 (2021); 92-100 ; Журнал инфектологии; Том 13, № 3 (2021); 92-100 ; 2072-6732 ; 10.22625/2072-6732-2021-13-3

مصطلحات موضوعية: HIV infection, raltegravir, drug-drug interactions, virological efficacy, undesirable side reactions, ВИЧ-инфекция, ралтегравир, межлекарственные взаимодействия, вирусологическая эффективность, нежелательные побочные реакции

وصف الملف: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/1244/921; Инструкция по применению препарата Исентресс® (Isentress); Гусев, Д.А. Современный пациент с ВИЧ-инфекцией: комплексная характеристика и выбор антиретровирусной терапии (по материалам Санкт-Петербургского Центра СПИД) / Д.А. Гусев [и др.] // Журнал инфектологии. — 2018. - Т.10, № 1. - С. 62-69.; Malika Sharma , Sharon L Walmsley «Raltegravir as antiretroviral therapy in HIV/AIDS» Expert Opin Pharmacother. 2014 Feb;15(3):395-405; Buchacz K, Wiegand R, Armon C, et al. Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study. HIV Clin Trials 2015; 16: 139-146; Squires K, Bekker L-G, Eron JJ, et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study. AIDS Res Hum Retroviruses 2013; 29: 859-870; D B Nugent, M Chowdhury , L J Waters «The changing face of an epidemic: healthy old age with HIV» Br J Hosp Med (Lond) 2017 Sep 2;78(9):516-522; L Calza , V Colangeli , E Magistrelli , L Bussini , M Conti , E Ramazzotti , R Mancini , P Viale Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infectionHIV Med2017 Aug;18(7):474-481; Giovanni Guaraldi , Jovana Milic, Cristina Mussini «Aging with HIVCurr HIV/AIDS» Rep. 2019 Dec;16(6):475-481; https://journal.niidi.ru/jofin/article/view/1244

الاتاحة: https://journal.niidi.ru/jofin/article/view/1244
https://doi.org/10.22625/2072-6732-2021-13-3-92-100

المؤلفون: N. Vatutin T., G. Taradin G., G. Ignatenko A., E. Gasendich S., A. Harchenko V., I. Povaljaeva B., Н. Ватутин Т., Г. Тарадин Г., Г. Игнатенко А., Е. Гасендич С., А. Харченко В., И. Поваляева Б.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 1 (2020); 40-45 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 1 (2020); 40-45 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: warfarin, anticoagulant effect, drug-drug interactions, international normalized ratio, варфарин, антикоагулянтный эффект, межлекарственные взаимодействия, международное нормализованное отношение

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2105/1932; Манешина О.А., Белоусов Ю.Б. Полипрагмазия и лекарственные взаимодействия у пожилых пациентов. Качественная Клиническая Практика. 2008;3:90-3.; Hanlon J., Schmader K., Koronkowski M., et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45(8):945-8. DOI:10.1111/j.1532-5415.1997.tb02964.x.; Отделенов В.А., Новакова А.И., Карасев А.В. и др. Оценка частоты потенциально значимых межлекарственных взаимодействий у больных с полипрагмазией в многопрофильном стационаре. Клиническая Фармакология и Терапия. 2012;21(5):81-5.; Лазебник Л.Б., Конев Ю.В., Дроздов В.Н., Ефремов Л.И. Полипрагмазия: гериатрический аспект проблемы. Consilium Medicum. 2007;12:29-34.; Ватутин Н.Т., Гасендич Е.С., Иофе Е.И. Случай приобретенной коагулопатии. Архивъ Внутренней Медицины. 2018;8(6):480-2. DOI:10.20514/2226-6704-2018-8-6-480-482.; Дземешкевич С.Л., Панченко Е.П. Антикоагулянтная терапия у пациентов с клапанными пороками сердца. Русский Медицинский Журнал. 2001;10:427-30.; Leite P.M., Martins M.A.P., Castilho R.O. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. Biomed Pharmacother. 2016;83:14-21. DOI:10.1016/j.biopha.2016.06.012.; Кропачева Е.С., Панченко Е.П., Добровольский А.Б., Саидова М.А. Резистентность к варфарину у больной с абсолютными показаниями к приему антагонистов витамина К. Атеротромбоз. 2009;1(2):99-104.; Tatsumi A., Kadobayashi M., Iwakawa S. Effect of ethanol on the binding of warfarin enantiomers to human serum albumin. Biol Pharm Bull. 2007;30(4):826-9. DOI:10.1248/bpb.30.826.; Fung E., Patsopoulos N.A., Belknap S.M., et al. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Thromb Hemost. 2012;38(8):893-904. DOI:10.1055/s-0032-1328891.; Al-Arifi M.N., Wajid S., Al-Manie N.K., et al. Evaluation of knowledge of health care professionals on warfarin interactions with drug and herb medicinal in Central Saudi Arabia. Pak J Med Sci. 2016;2(1):229-233. DOI:10.12669/pjms.321.8902.; Инструкция по применению лекарственного препарата для медицинского применения Аллохол [цитировано 10.08.2019. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ba3f0e46-5098-46e4-933f172319b8ff7f&t=.; Bielecki S., Dolim Lee D., Hamad B. The market for oral anticoagulants. Nature Reviews Drug Discovery. 2018;17:617-8. DOI:10.1038/nrd.2018.89.; Jaiswal P., Shinde S. Anticoagulants market-global opportunity analysis and industry forecast, 2018-2025. Allied Market Research. 2018. [cited by Oct 08, 2019]. Available from: https://www.alliedmarketresearch.com/anticoagulant-drugs-market .; Pirmohamed M. Warfarin: the end or the end of one size fits all therapy? J Pers Med. 2018;8(3):piiE22. DOI:10.3390/jpm8030022.; Скирденко Ю.П., Николаев Н.А. Новые подходы к индивидуализированному выбору пероральных антикоагулянтов у больных фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2018;14(1):58-64 DOI:10.20996/1819-6446-2018-14-1-58-64.; Марцевич С.Ю., Лукина Ю.В. Варфарин и его значение в эру новых оральных антикоагулянтов. Вопросы контроля эффективности и безопасности лечения. Рациональная Фармакотерапия в Кардиологии. 2017;13(5):699-705. DOI:10.20996/1819-6446-2017-13-5-699-705.; Durães A.R., de Souza Lima Bitar Y., Filho J.A.L, et al. Rivaroxaban versus warfarin in patients with mechanical heart valve: rationale and design of the RIWA Study. Drugs R D. 2018;18(4):303-8. DOI:10.1007/s40268-018-0249-5.; Macan H., Uykimpang R., Alconcel M., et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136(3 Suppl):793S-795S. DOI:10.1093/jn/136.3.793S.; Choi S., Oh D.S., Jerng U.M. A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin. PLoS One. 2017;12(8):e0182794. DOI:10.1371/journal.pone.0182794.; Rahman K. Effects of garlic on platelet biochemistry and physiology. Mol Nutr Food Res. 2007;51(11):1335-44. DOI:10.1002/mnfr.200700058.; Mohammed Abdul M.I., Jiang X., Williams K.M., et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008;154(8):1691-700. DOI:10.1038/bjp.2008.210.; Fasinu P.S., Bouic P.J., Rosenkranz B. An overview of the evidence and mechanisms of herbdrug interactions. Front Pharmacol. 2012;3:69. DOI:10.3389/fphar.2012.00069.; Lutomski J., Speichert H. Die Brennessel in Heilkunde und Ernährung. Pharmazie in unserer Zeit. 1983;12:181-6. DOI:10.1002/pauz.19830120602.; Biró-Sándor Z. Assessment report on Urtica Dioica L., and Urtica Urens L., herba. London: European Medicines Agency; 2008.; Dhouibi R., Affes H., Ben Salem M., et al. Screening of pharmacological uses of Urtica dioica and others benefits. Prog Biophys Mol Biol. 2020;150:67-77. DOI:10.1016/j.pbiomolbio.2019.05.008.; McDowell L.R. Vitamins in animal and human nutrition. 2nd Edition. New York: John Wiley & Sons; 2008.; https://www.rpcardio.com/jour/article/view/2105

الاتاحة: https://www.rpcardio.com/jour/article/view/2105
https://doi.org/10.20996/1819-6446-2020-02-01

المؤلفون: D. A. Sychev, V. A. Otdelenov, N. P. Denisenko, V. V. Smirnov, Д. А. Сычёв, В. А. Отделенов, Н. П. Денисенко, В. В. Смирнов

المصدر: Pharmacogenetics and Pharmacogenomics; № 2 (2016); 4-11 ; Фармакогенетика и фармакогеномика; № 2 (2016); 4-11 ; 2588-0527 ; 2686-8849

مصطلحات موضوعية: неблагоприятные побочные реакции, the cytochrome P450, drug-drug interaction, phenotyping, adverse drug reactions, цитохром Р450, межлекарственные взаимодействия, фенотипирование

وصف الملف: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/172/172; Hodgson, E. (2004). A textbook of modern toxicology, John Wiley & Sons, Inc., Retrieved from http://faculty.ksu.edu.sa/73069/Documents/Toxicology.pdf; Gundert-Remy U., Bernauer U., Blömeke B., Döring B., Fabian E., Goebel C., Hessel S., Jäckh C., Lampen A., Oesch F., Petzinger E., Völkel W., Roos P.H. Extrahepatic metabolism at the body’s internal-external interfaces. Drug Metab Rev. 2014 Aug;46(3):291-324.; Manevski N., Swart P., Balavenkatraman K.K., Bertschi B., Camenisch G., Kretz O., Schiller H., Walles M., Ling B., Wettstein R., Schaefer D.J., Itin P., Ashton-Chess J., Pognan F., Wolf A., Litherland K. Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation. Drug Metab Dispos. 2014 Oct 22.; Tomlin Mark E. Pharmacology & Pharmacokinetics a Basic Reader. New York: Springer, 2010.; Williams J.A., Hyland R., Jones B.C., Smith D.A., Hurst S., Goosen T.C., Peterkin V., Koup J.R., Ball S.E. Drug-drug interactions for UDP-glucuronosyltransferasesubstrates: a pharmacokinetic explanation for typically observed low exposure(AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov; 32 (11): 1201–8.; Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997 Feb-May; 29 (1–2): 413–580.; Pandit Nita K.,Robert P. Soltis. Introduction to the Pharmaceutical Sciences: An Integrated Approach. 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins, 2012.; Kaminsky L.S., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73 (1): 67–74.; Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport:comparison with the effects on CYP3A4. Pharm Res. 2000 Oct; 17(10): 1189–97.; Rodrigues A.D., Roberts E.M., Mulford D.J., Yao Y., Ouellet D. Oxidative metabolismof clarithromycin in the presence of human liver microsomes. Major role for thecytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos. 1997 May; 25 (5): 623–30.; Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999 Dec; 84 (3): 413–28.; Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J., Sinnaeve P., Camm A.J., Kirchhof P. European Heart Rhythm Association. European Heart RhythmAssociation Practical Guide on the use of new oral anticoagulants in patientswith non-valvular atrial fibrillation. Europace. 2013 May; 15 (5): 625–51.; Bertilsson L., Tybring G., Widen J., Chang M., Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997; 44 (2): 186–189.; Ohno M., Motojima K., Okano T., Taniguchi A. Induction of drugmetabolizingenzymes by phenobarbital in layered co-culture of a human liver cell line andendothelial cells. Biol Pharm Bull. 2009 May; 32 (5): 813–7.; Fleishaker J.C., Pearson L.K., Peters G.R. Phenytoin causes a rapid increase in 6beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3Ainduction. J Pharm Sci. 1995 Mar; 84 (3): 292–4.; Backman J.T., Olkkola K.T., Neuvonen P.J. Rifampin drastically reduces plasmaconcentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996 Jan; 59 (1): 7–13.; Rahimi R., Abdollahi M. An update on the ability of St. John’s wort to affectthe metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012 Jun; 8 (6): 691–708.; Varhe A., Olkkola K.T., Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 56 (6 Pt 1): 601–607.; Eagling V.A., Back D.J., Barry M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997; 44 (2): 190–194.; Akiyoshi T., Ito M., Murase S., Miyazaki M., Guengerich F.P., Nakamura K., Yamamoto K., Ohtani H. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. Drug Metab Pharmacokinet. 2013; 28 (5): 411–5.; Chan A.T., Zauber A.G., Hsu M., Breazna A., Hunter D.J., Rosenstein R.B., Eagle C.J., Hawk E.T., Bertagnolli M.M. Cytochrome P450 2C9 variants influence response tocelecoxib for prevention of colorectal adenoma. Gastroenterology. 2009Jun; 136 (7): 2127–2136. e1.; Morin S., Loriot M.A., Poirier J.M., Tenneze L., Beaune P.H., FunckBrentano C., Jaillon P., Becquemont L. Is diclofenac a valuable CYP2C9 probe in humans? Eur JClin Pharmacol. 2001 Jan-Feb; 56 (11): 793–7.; Berka K., Hendrychová T., Anzenbacher P., Otyepka M. Membrane position ofibuprofen agrees with suggested access path entrance to cytochrome P450 2C9active site. J Phys Chem A. 2011 Oct 20; 115 (41): 11248–55.; Guo Y., Zhang Y., Wang Y., Chen X., Si D., Zhong D., Fawcett J.P., Zhou H. Role ofCYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005 Jun; 33 (6): 749–53.; Chesné C., Guyomar C., Guillouzo A., Schmid J., Ludwig E., Sauter T. Metabolism ofMeloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan; 28 (1): 113.; Bae J.W., Kim J.H., Choi C.I., Kim M.J., Kim H.J., Byun S.A., Chang Y.S., Jang C.G., Park Y.S., Lee S.Y. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Koreansubjects. Arch Pharm Res. 2009 Feb; 32 (2): 269–73.; Zhang Y.F., Chen X.Y., Guo Y.J., Si D.Y., Zhou H., Zhong D.F. Impact of cytochrome P450 CYP2C9 variant allele CYP2C9*3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects. Yao Xue Xue Bao. 2005; 40: 796–799.; Niemi M., Cascorbi I., Timm R., Kroemer H.K., Neuvonen P.J., Kivisto K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002; 72: 326–332.; Kidd R.S., Straughn A.B., Meyer M.C., Blaisdell J., Goldstein J.A., Dalton J.T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999; 9: 71–80.; Kirchheiner J., Bauer S., Meineke I., Rohde W., Prang V., Meisel C., Roots I., Brockmöller J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kineticsand the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002 Mar; 12 (2): 101–9.; Chen G., Jiang S., Mao G., Zhang S., Hong X., Tang G., Li Z., Liu X., Zhang Y., Xing H.,Wang B., Yu Y., Xu X. CYP2C9 Ile359Leu polymorphism, plasma irbesartanconcentration and acute blood pressure reductions in response to irbesartantreatment in Chinese hypertensive patients. Methods Find Exp Clin Pharmacol. 2006 Jan–Feb; 28 (1): 19–24.; McCrea J.B., Cribb A., Rushmore T., Osborne B., Gillen L., Lo M.W., Waldman S., Bjornsson T., Spielberg S., Goldberg M.R. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its activemetabolite E-3174. Clin Pharmacol Ther. 1999 Mar; 65 (3): 348–52.; Food and Drug Administration: Table of Pharmacogenomic Biomarkers in Drug Labeling. URL: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm; Veronese M.E., Mackenzie P.I., Doecke C.J., McManus M.E., Miners J.O., Birkett D.J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 1991; 175: 1112–1118.; Coller J.K., Krebsfaenger N., Klein K., Endrizzi K., Wolbold R., Lang T., Nüssler A., Neuhaus P., Zanger U.M., Eichelbaum M., Mürdter T.E. The influence of CYP2B6, CYP2C9and CYP2D6 genotypes on the formation of the potent antioestrogenZ-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol. 2002 Aug; 54 (2): 157–67.; Ekhart C., Doodeman V.D., Rodenhuis S., Smits P.H., Beijnen J.H., Huitema A.D. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008; 18: 515–523.; Griskevicius L., Yasar U., Sandberg M., Hidestrand M., Eliasson E., Tybring G., Hassan M., Dahl M.L. Bioactivation of cyclophosphamide: the role of polymorphicCYP2C enzymes. Eur J Clin Pharmacol. 2003 Jun; 59 (2): 103–9.; Rana R., Chen Y., Ferguson S.S., Kissling G.E., Surapureddi S., Goldstein J.A. Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos. 2010 Apr; 38 (4): 591–9.; Kaukonen K.M., Olkkola K.T., Neuvonen P.J. Fluconazole but not itraconazoledecreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol. 1998Feb; 53 (6): 445–9.; Wu X., Yuan L., Zuo J., Lv J., Guo T. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects. Eur J Clin Pharmacol. 2014 Jan; 70 (1): 57–63.; Preskorn S.H., Shah R., Neff M., Golbeck A.L., Choi J. The potential for clinicallysignificant drug-drug interactions involving the CYP 2D6 system: effects withfluoxetine and paroxetine versus sertraline. J Psychiatr Pract. 2007 Jan; 13 (1): 5–12.; O’Hara G.E., Philippon F., Gilbert M., Champagne J., Michaud V., Charbonneau L., Pruneau G., Hamelin B.A., Geelen P., Turgeon J. Combined Administration of Quinidine and Propafenone for Atrial Fibrillation: The CAQ-PAF Study. J Clin Pharmacol. 2012 Feb; 52 (2): 171–9.; Spina E., Santoro V., D’Arrigo C. Clinically relevant pharmacokinetic druginteractions with second-generation antidepressants: an update. Clin Ther. 2008 Jul; 30 (7): 1206–27.; Haertter S. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6. Drug Metabol Drug Interact. 2013; 28 (4): 209–16.; Rae J.M., Johnson M.D., Lippman M.E., Flockhart D.A. Rifampin is a selective,pleiotropic inducer of drug metabolism genes in human hepatocytes: studies withcDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001 Dec; 299 (3): 849–57.; Wadelius M., Darj E., Frenne G., Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997 Oct; 62 (4): 400–7.; Ayari I., Fedeli U., Saguem S., Hidar S., Khlifi S., Pavanello S. Role of CYP1A2 polymorphisms in breast cancer risk in women. Mol Med Rep. 2013 Jan; 7 (1): 280–6.; Fontana R.J., Lown K.S., Paine M.F., Fortlage L., Santella R.M., Felton J.S., Knize M.G.,Greenberg A., Watkins P.B. Effects of a chargrilled meat diet on expression ofCYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology. 1999 Jul; 117 (1): 89–98.; Hakooz N., Hamdan I. Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab. 2007 Jan; 8 (1): 9–15.; Karjalainen M.J., Neuvonen P.J., Backman J.T. In vitro inhibition of CYP1A2 bymodel inhibitors, anti-inflammatory analgesics and female sex steroids:predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug; 103 (2): 157–65.; Rendic S. Summary of information on human CYP enzymes: human P450 metabolismdata. Drug Metab Rev. 2002 Feb-May; 34 (1–2): 83–448.; Ritter, James. A Textbook of Clinical Pharmacology and Therapeutics. 5th ed. London: Hodder Arnold, 2008.; Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007 Dec; 116 (3): 496–526.; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf; Michaut A., Moreau C., Robin M.A., Fromenty B. Acetaminopheninduced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int. 2014 Aug; 34 (7): e171–9.; Tompkins L.M., Wallace A.D. Mechanisms of cytochrome P450 induction. J BiochemMol Toxicol. 2007; 21 (4): 176–81.; Azzalis L.A., Fonseca F.L., Simon K.A., Schindler F., Giavarotti L., Monteiro H.P., Videla L.A., Junqueira V.B. Effects of ethanol on CYP2E1 levels and relatedoxidative stress using a standard balanced diet. Drug Chem Toxicol. 2012 Jul; 35 (3): 324–9.; Brewer L., Williams D. Clinically Relevant Drug-Drug and Drug-Food Interactions. Pharmaceutical medicine. 2013. 27 (1): 9–23.; European Medicines Agency. Committee for Human Medicinal Products. Guideline on the Investigation of Drug Interactions 2012. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf; Сычев Д.А. Рекомендации для фармацевтических компаний по изучению биотрансформации и транспортеров новых лекарственных средств: дизайн исследований, анализ данных и внесение информации в инструкции по применению. /Науч. ред. В. Г. Кукес. М.: 2009.URL: http://www.regmed.ru/Content/Doc.aspx?id=26a9128c-ee32-4469-9c645c666339049e; Shin K.H., Choi M.H., Lim K.S., Yu K.S., Jang I.J., Cho J.Y. Evaluation of endogenousmetabolic markers of hepatic CYP3A activity using metabolic profiling andmidazolam clearance. Clin Pharmacol Ther. 2013 Nov; 94 (5): 601–9.; Yasar U., Forslund-Bergengren C., Tybring G., Dorado P., Llerena A., Sjöqvist F., Eliasson E., Dahl M.L. Pharmacokinetics of losartan and its metabolite E-3174 inrelation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan; 71 (1): 89–98.; Stearns R.A., Chakravarty P.K., Chen R., Chiu S.H. Biotransformation of losartan toits active carboxylic acid metabolite in human liver microsomes. Role ofcytochrome P4502C and 3A subfamily members. Drug Metab Dispos. 1995 Feb; 23 (2): 207–15.; Yun C.H., Lee H.S., Lee H., Rho J.K., Jeong H.G., Guengerich F.P. Oxidation of theangiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes.Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. DrugMetab Dispos. 1995 Feb; 23 (2): 285–9.; Yasar U., Tybring G., Hidestrand M., Oscarson M., Ingelman-Sundberg M., Dahl M.L., Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos. 2001 Jul; 29 (7): 1051–6.; de Andrés F, Sosa-Macías M, Llerena A. A rapid and simple LC-MS/ MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4hydroxylation capacity. Bioanalysis. 2014 Mar; 6 (5): 683–96.; Dorado P., Gallego A., Peñas-LLedó E., Terán E., Lerena A. Relationship betweenthe CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthyEcuadorian volunteers. Pharmacogenomics. 2014 Aug; 15 (11): 1417–21.; Sekino K., Kubota T., Okada Y., Yamada Y., Yamamoto K., Horiuchi R., Kimura K., Iga T. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol. 2003 Nov; 59 (8–9): 589–92.; Galteau M.M., Shamsa F. Urinary 6beta-hydroxycortisol: a validated test forevaluating drug induction or drug inhibition mediated through CYP3A in humans andin animals. Eur J Clin Pharmacol. 2003 Dec; 59 (10): 713–33.; https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/172

الاتاحة: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/172

المؤلفون: D. A. Gusev, N. V. Sizova, S. O. Mayorova, V. V. Bratkova, A. L. Sotnikova, T. V. Malkova, Д. А. Гусев, Н. В. Сизова, С. О. Майорова, В. В. Браткова, А. Л. Сотникова, Т. В. Малькова

المصدر: Journal Infectology; Том 10, № 1 (2018); 62-69 ; Журнал инфектологии; Том 10, № 1 (2018); 62-69 ; 2072-6732 ; 10.22625/2072-6732-2018-10-1

مصطلحات موضوعية: межлекарственные взаимодействия, ART, comorbidities, drug-drug interactions, АРТ, сопутствующие заболевания

وصف الملف: application/pdf

Relation: https://journal.niidi.ru/jofin/article/view/696/604; Справка. ВИЧ-инфекция в Российской Федерации на 31 декабря 2016 года. Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФБУН Центрального НИИ эпидемиологии Роспотребнадзора.; Беляков, Н.А. Эволюция ВИЧ-инфекции в Санкт- Петербурге – снижение заболеваемости, старение и утяжеление болезни / Н.А. Беляков [и др.] // ВИЧ-инфекция и иммуносупрессии. – 2015. – № 2, Т. 7. – С. 7–17.; Сизова, Н.В. Особенности антиретровирусной терапии и эволюция лекарственной устойчивости в условиях мегаполиса : автореф. …дис. д-ра мед. наук / Н.В. Сизова. – СПб., 2014. – 44с.; Лиознов, Д.А. Характеристика эпидимиологической ситуации по ВИЧ-инфекции в Северно-Западном Феде- ральном округе Российской Федерации / Д.А. Лиознов [и др.] // ВИЧ-инфекция и иммуносупрессии – 2015. – № 2, Т. 7 – С. 93–100.; Покровский, В.В. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией 2016 / В.В. Покровский [и др.] // Эпидемиология и инфекционные болезни. Актуальные вопросы. – 2016. – № 6, приложение 1. – 112 с.; Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 8.1; October, 2016). European AIDS Clinical Society (http://www. europeanaidsclinicalsociety.org).; ВИЧ 2014/15 г. / под ред. К. Хоффман, Ю. К. Рокштро. – М., 2014. – 924 с. – www.hivbuch.de; https://journal.niidi.ru/jofin/article/view/696

الاتاحة: https://journal.niidi.ru/jofin/article/view/696
https://doi.org/10.22625/2072-6732-2018-10-1-62-69

المؤلفون: A. D. Abdrashitov, G. N. Gildeeva, G. V. Ramenskaya, V. V. Smirnov

المصدر: Фармакокинетика и Фармакодинамика, Vol 0, Iss 1, Pp 4-11 (2014)

مصطلحات موضوعية: биотрансформация, межлекарственные взаимодействия, фенотипирование, cyp2d6, цитохром р450, пинолин, персонализированная медицина, biotransformation, drug interactions, phenotyping, cytochrome p450, pinoline, personalized medicine, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.pharmacokinetica.ru/jour/article/view/147; https://doaj.org/toc/2587-7836; https://doaj.org/toc/2686-8830

URL الوصول: https://doaj.org/article/bce9cc55c3dc44e78161ba07eec4caa5

المؤلفون: E. Ilina S., O. Bogova T., S. Gorbatenkova V., D. Sychev A., Е. Ильина С., О. Богова Т., С. Горбатенкова В., Д. Сычев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 13, No 2 (2017); 203-206 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 2 (2017); 203-206 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-2

مصطلحات موضوعية: elderly patient, multimorbidity, polypragmasy, falling, fall risk-increasing drugs, adverse drug reaction, Horn-Hansten scale, drug-drug interactions, геронтологический пациент, мультиморбидность, полипрагмазия, падение, лекарственные средства, повышающие риск падения, нежелательная лекарственная реакция, шкала Horn-Hansten, межлекарственные взаимодействия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1448/1478; Sychev D.A. Polypharmacy in Clinical Practice: Problem and Solutions, Manual for Physicians. St. Petersburg: TSOP "Professia"; 2016. (In Russ) [Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения, Учебное пособие для врачей. СПб.: ЦОП "Профессия"; 2016].; Dvoretsky L.I. Iatrogenic events in elderly patients. Vrach. 2012;(5):14-7. (In Russ.) [Дворецкий Л.И. Ятрогенные события у пожилых больных. Врач. 2012;(5):14-7].; Ostroumova O.D., Batutina A.M., Zykova A.A. Patient interaction: are there "ideal" drugs for use in polypharmacy conditions? Russkii Meditsinskii Zhurnal. 2003;21:1152. (In Russ.) [Остроумова О.Д., Батутина А.М., Зыкова А.А. Лекарственное взаимодействие: существуют ли "идеальные" лекарственные препараты для использования в условиях полипрагмазии? Русский Медицинский Журнал. 2003;21:1152].; Ilyina E.S., Sychev DA, Bogova O.T. Medicines as a risk factor for falls of gerontological patients with cardiovascular diseases with polymorbidity. Vestnik Vserossiyskogo Obshchestva Spetsialistov po Medikosotsial'noy Ekspertize, Reabilitatsii i Reabilitatsionnoy Industrii. 2015; (4): 111-8. (In Russ.) [Ильина Е.С., Сычев Д.А., Богова О.Т. Лекарственные средства как фактор риска падений геронтологических пациентов с сердечно-сосудистыми заболеваниями с полиморбидностью. Вестник Всероссийского Общества Специалистов по Медико-социальной Экспертизе, Реабилитации и Реабилитационной Индустрии. 2015;(4):111-8].; Kazakov A.S. Determination of the degree of reliability of causation "adverse reaction - drugs interaction". Russkii Meditsinskii Zhurnal. 2013;(5):38-43. (In Russ.) [Казаков А.С. Определение степени достоверности причинно-следственной связи "Нежелательная реакция – взаимодействие лекарственных средств". Русский Медицинский Журнал. 2013;(5):38-43].; Horn J.R., Hansten P.D., Chan L.N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674-80.; Juurlink D.N., Mamdani M., Kopp A., et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. The Journal of the American Medical Association. 2003;289:652-8.; Lepakhin V.K., Astakhova A.V., Ushkalova E.A., et al. Development of methods for studying and preventing complications of pharmacotherapy. Tutorial. Moscow: RUDN; 2008. (In Russ.) [Лепахин В.К., Астахова А.В., Ушкалова Е.А., и др. Разработка методов изучения и профилактики осложнений фармакотерапии. Учебное пособие. Москва: РУДН; 2008].; Butt D.A., Mamdani M., Austin P.C., et al The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739-44.; Darowski A., Dwight J., Reynolds J., Radcliffe J. Medicines and Falls in Hospital: Guidance Sheet, National Institute for Health and Clinical Excellence guidelines. Available at: http://www.bgs.org.uk/campaigns/ fallsafe/Falls_drug_guide.pdf. Checked by April 09, 2017.; Huang A.R., Mallet L., Rochefort C.M., et al. Medication-Related Falls in the Elderly. Drugs & Aging. 2012;29(5):359-76.; Dutta R. Falls in older people. Guidelines in Practice. 2014;17(6):52-9. 13. Horn J.R., Hansten D. How to assess drug interaction: case reports. Pharmacy Times. 2006;72:26.; https://www.rpcardio.com/jour/article/view/1448

الاتاحة: https://www.rpcardio.com/jour/article/view/1448
https://doi.org/10.20996/1819-6446-2017-13-2-203-206

المؤلفون: D. A. Sychjov, L. K. Moshetova, Дмитрий Алексеевич Сычев, Л. К. Мошетова

المصدر: National Journal glaucoma; Том 13, № 2 (2014); 99-104 ; Национальный журнал Глаукома; Том 13, № 2 (2014); 99-104 ; 2311-6862 ; 2078-4104

مصطلحات موضوعية: drug-drug interaction, глаукома, сердечно-сосудистые заболевания, неблагоприятные реакции, межлекарственные взаимодействия, clinical pharmacology, glaucoma, cardiovascular diseases, adverse drug reactions

وصف الملف: application/pdf

Relation: https://www.glaucomajournal.ru/jour/article/view/21/22; Шальнова С.А., Конради А.О., Карпов Ю.А., Концевая А.В., Деев А.Д., Капустина А.В., Худяков М.Б., Шляхто Е.В., Бойцов С.А. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал 2012; 5(97): 6-11; Беленков Ю.Н., Оганов Р.Г. Кардиология. Национальное руководство. Москва: Гэотар-Медиа; 2012. 848 с; Егоров Е.А., Астахов Ю.С., Щуко А.Г. Национальное руководство (путеводитель) по глаукоме для поликлинических врачей. Москва, Столичный бизнес, 2008; 136 c; Saxena R., Prakash J., Gupta S. Pharmacotherapy of glaucoma. Indian Journal of Pharmacology 2002; 34: 71-85.; Nieminen T., Lehtimki T., Mäenpää J., Ropo A., Uusitalo H., Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007; 67(2): 237-245.; Goldberg I., Moloney G., McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications. Med J Aust 2008; 189(7): 406-407.; Клиническая фармакология по Гудману и Гилману / Под ред. А.Г. Гилмана. М.: Практика; 2006. 2850 с.; Zimmerman F.H., Cameron A., Fisher L.D., Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26(3): 654-661.; Müskens R.P., Wolfs R.C., Witteman J.C., Hofman A., de Jong P.T., Stricker B.H., Jansonius N.M. Topical beta-blockers and mortality. Ophthalmology 2008; 115(11): 2037-2043.; Ergin A., Ornek K., Giillii R., Bulcun E., Ekici M., Ekici A. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma. J Ocul Pharmacol Ther 2009; 25(5): 463-466.; Waldock A., Snape J., Graham C.M. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84(7): 710-713.; Stewart W.C., Stewart J.A., Jackson A.L. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol male-ate in concomitant therapy. Acta Ophthalmol Scand 2002; 80(3): 277-281.; Krasińska B., Karolczak-Kulesza M., Krasiński Z., Pawlaczyk-Gabriel K., Lopatka P., Głuszek J., Tykarski A. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press 2012; 21(4): 240-248.; Grunwald J.E., DuPont J., Dreyer E.B. Effect of chronic nitrate treatment on retinal vessel caliber in open-angle glaucoma. Am J Ophthalmol 1997; 123(6): 753-758.; Wizemann A.J., Wizemann V. Organic nitrate therapy in glaucoma. Am J Ophthalmol 1980; 90(1): 106-109.; Marcus M.W., Müskens R.P., Ramdas W.D., Wolfs R.C., de Jong P.T., Vingerling J.R., Hofman A., Stricker B.H., Jansonius N.M. Antithrombotic medication and incident open-angle glaucoma. Invest Ophthalmol Vis Sci 2012; 53(7): 3801-3805.; Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств: научные основы персонализированной медицины. М.: ГЭОТАР-Медиа; 2008; 304 с.; Курышева Н.И., Брежнев А.Ю., Капкова С.Г. Распространенность псевдоэксфолиативной глаукомы в Центральном и Центрально-Черноземном регионах России. Глаукома 2008; 3: 11-15; Авдеев Р.В., Александров А.С., Басинский А.С., Блюм Е.А., Брежнев А.Ю., Волков Е.Н. и др. Клинико-эпидемиологическое исследование факторов риска развития и прогрессирования глаукомы. Российский офтальмологический журнал 2013; 6(3): 4-11; Egorov E., Ropo A., Erichev V., Astakhov Y., Alekseev V., Takhchidi K., et al. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol 2009; 19(2): 214-222; https://www.glaucomajournal.ru/jour/article/view/21

الاتاحة: https://www.glaucomajournal.ru/jour/article/view/21

المؤلفون: МУСИНА А.З., СЕЙТМАГАНБЕТОВА Н.А., ЖАМАЛИЕВА Л.М., СМАГУЛОВА Г.А., ГРЖИБОВСКИЙ А.М.

مصطلحات موضوعية: ПОЛИПРАГМАЗИЯ,НЕЖЕЛАТЕЛЬНАЯ ПОБОЧНАЯ РЕАКЦИЯ,МЕЖЛЕКАРСТВЕННЫЕ ВЗАИМОДЕЙСТВИЯ,ОПТИМИЗАЦИЯ ФАРМАКОТЕРАПИИ,КРИТЕРИЙ БИРСА,STOPP/START КРИТЕРИИ,ЖАғЫМСЫЗ қОСЫМША РЕАКЦИЯ,ДәРіАРАЛЫқ өЗАРА әСЕРЛЕР,ФАРМАКОТЕРАПИЯНЫ ОңТАЙЛАНДЫРУ,БИРС КөРСЕТКіШі,STOPP/START КөРСЕТКіШТЕРі,POLYPHARMACY,UNWANTED SIDE EFFECTS,DRUG INTERACTIONS,OPTIMIZATION OF PHARMACOTHERAPY,BEERS CRITERIA,STOPP/START CRITERIA

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/indikatory-otsenki-ratsionalnosti-lekarstvennoy-terapii
http://cyberleninka.ru/article_covers/16553192.png

المؤلفون: АБДРАШИТОВ РУСТЕМ ХАМЗИЕВИЧ, ГИЛЬДЕЕВА Г.Н., РАМЕНСКАЯ Г.В., СМИРНОВ В.В.

مصطلحات موضوعية: БИОТРАНСФОРМАЦИЯ, МЕЖЛЕКАРСТВЕННЫЕ ВЗАИМОДЕЙСТВИЯ, ФЕНОТИПИРОВАНИЕ, ЦИТОХРОМ Р450, ПИНОЛИН, ПЕРСОНАЛИЗИРОВАННАЯ МЕДИЦИНА

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/obzor-suschestvuyuschih-metodik-otsenki-aktivnosti-cyp2d6-s-primeneniem-ekzogennyh-i-endogennyh-markerov
http://cyberleninka.ru/article_covers/15914829.png

المؤلفون: ТКАЧ С.М., ОНИЩУК Л.А.

مصطلحات موضوعية: ИНГИБИТОРЫ ПРОТОННОЙ ПОМПЫ,PROTON POMP INHIBITORS,МЕЖЛЕКАРСТВЕННЫЕ ВЗАИМОДЕЙСТВИЯ,DRUG INTERACTIONS,СИСТЕМА ЦИТО- ХРОМА Р450,CYTOCHROME P450 SYSTEM,ПАНТОПРАЗОЛ,PANTOPRAZOLE

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/ingibitory-protonnoy-pompy-i-risk-mezhlekarstvennyh-vzaimodeystviy
http://cyberleninka.ru/article_covers/16050446.png

المؤلفون: Абаимов, Д., Сариев, А., Носкова, Т., Шведков, В., Ширяева, М., Стырова, Е., Прохоров, Д., Сейфулла, Р.

مصطلحات موضوعية: ТЕРАПЕВТИЧЕСКИЙ ЛЕКАРСТВЕННЫЙ МОНИТОРИНГ, ПРОТИВОЭПИЛЕПТИЧЕСКИЕ ПРЕПАРАТЫ, СВОБОДНАЯ И СВЯЗАННАЯ ФРАКЦИИ ПРЕПАРАТА, РАВНОВЕСНЫЙ ДИАЛИЗ, ФАРМАКОГЕНЕТИЧЕСКОЕ ТЕСТИРОВАНИЕ, НЕИНВАЗИВНЫЙ ТЛМ, ХРОМАТОГРАФИЯ, МАСС-СПЕКТРОМЕТРИЯ, ПОПУЛЯЦИОННОЕ ФАРМАКОКИНЕТИЧЕСКОЕ КОМПЬЮТЕРНОЕ МОДЕЛИРОВАНИЕ, МЕЖЛЕКАРСТВЕННЫЕ ВЗАИМОДЕЙСТВИЯ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/sovremennye-tehnologii-v-terapevticheskom-lekarstvennom-monitoringe
http://cyberleninka.ru/article_covers/14504525.png

المصدر: Наука и здравоохранение.

مصطلحات موضوعية: ПОЛИПРАГМАЗИЯ,НЕЖЕЛАТЕЛЬНАЯ ПОБОЧНАЯ РЕАКЦИЯ,МЕЖЛЕКАРСТВЕННЫЕ ВЗАИМОДЕЙСТВИЯ,ОПТИМИЗАЦИЯ ФАРМАКОТЕРАПИИ,КРИТЕРИЙ БИРСА,STOPP/START КРИТЕРИИ,ЖАғЫМСЫЗ қОСЫМША РЕАКЦИЯ,ДәРіАРАЛЫқ өЗАРА әСЕРЛЕР,ФАРМАКОТЕРАПИЯНЫ ОңТАЙЛАНДЫРУ,БИРС КөРСЕТКіШі,STOPP/START КөРСЕТКіШТЕРі,POLYPHARMACY,UNWANTED SIDE EFFECTS,DRUG INTERACTIONS,OPTIMIZATION OF PHARMACOTHERAPY,BEERS CRITERIA,STOPP/START CRITERIA

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2806::8b04c99c3d4d2d043eb6a430208166c8
http://cyberleninka.ru/article_covers/16553192.png

مصطلحات موضوعية: Beers criteria, Бирс көрсеткіші, дәріаралық өзара әсерлер, drug interactions, критерий Бирса, полипрагмазия, STOPP/START көрсеткіштері, межлекарственные взаимодействия, unwanted side effects, оптимизация фармакотерапии, фармакотерапияны оңтайландыру, optimization of pharmacotherapy, polypharmacy, нежелательная побочная реакция, STOPP/START criteria. Түйін, STOPP/START критерии, жағымсыз қосымша реакция

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::26f3a26cebbac6997031db14a583b0a7

المؤلفون: S.M. Tkach, L.A. Onishchuk

المصدر: GASTROENTEROLOGY; № 2.56 (2015); 91-98
Гастроэнтерология-Gastroenterologìa; № 2.56 (2015); 91-98
Гастроентерологія-Gastroenterologìa; № 2.56 (2015); 91-98

مصطلحات موضوعية: Drug, Proton, Chemistry, media_common.quotation_subject, ингибиторы протонной помпы, межлекарственные взаимодействия, система цито-хрома Р450, пантопразол, proton pomp inhibitors, drug interactions, cytochrome P450 system, pantoprazole, інгібітори протонної помпи, міжлікарські взаємодії, система Р450, Combinatorial chemistry, media_common

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34383fd3afb69034a187bcd8876a7d60
http://gastro.zaslavsky.com.ua/article/view/81503